Pet Pharm Biotech Co (ROCO:7762) Marketable Securities: NT$250.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7762 Pet Pharm Biotech Co Ltd ROCO:7762
19 GF Score
Price NT$58.00
! 5 Warning Signs
View Full Analysis

What is Pet Pharm Biotech Co Marketable Securities?

Pet Pharm Biotech Co ROCO:7762 -0.68% 19 Marketable Securities is NT$250.2 Mil as of Dec. 2025. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Pet Pharm Biotech Co's Marketable Securities for the quarter that ended in Dec. 2025 was NT$250.2 Mil.

Pet Pharm Biotech Co's annual Marketable Securities increased from Dec. 2023 (NT$141.0 Mil) to Dec. 2024 (NT$206.1 Mil) and increased from Dec. 2024 (NT$206.1 Mil) to Dec. 2025 (NT$250.2 Mil).

Pet Pharm Biotech Co  (ROCO:7762) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Pet Pharm Biotech Co Marketable Securities Related Terms

Pet Pharm Biotech Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Pet Pharm Biotech Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pet Pharm Biotech Co Marketable Securities Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Marketable Securities
50.00 141.00 206.14 250.21

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial 141.00 191.16 206.14 250.20 250.21
ROCO:7762
19GF Score
Pet Pharm Biotech Co Ltd ROCO:7762
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pet Pharm Biotech Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$250.2 Mil mean?
Pet Pharm Biotech Co (ROCO:7762) has a Marketable Securities of NT$250.2 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pet Pharm Biotech Co and its competitors.
Is Pet Pharm Biotech Co's Marketable Securities too high?
Pet Pharm Biotech Co's current Marketable Securities is NT$250.2 Mil. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's Marketable Securities compare to LLY and JNJ?
Pet Pharm Biotech Co's Marketable Securities of NT$250.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pet Pharm Biotech Co and its competitors. Pet Pharm Biotech Co's current Marketable Securities is NT$250.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current Marketable Securities of NT$250.2 Mil. The current Marketable Securities is NT$250.2 Mil. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current Marketable Securities is NT$250.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pet Pharm Biotech Co Business Description

Address 143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score

Get the complete analysis for ROCO:7762

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$58.00
Price